McCormick shares maintain Hold rating from HSBC

Published 02/10/2024, 11:36
McCormick shares maintain Hold rating from HSBC

McCormick (NYSE:MKC) & Company (NYSE: MKC) saw its price target modestly increase by an analyst at HSBC from $79.00 to $80.00, while the Hold rating on the stock remained unchanged.

The adjustment follows the company's release of its third-quarter financial results for fiscal year 2024, which showcased a stronger performance than market expectations.

The spice and flavorings manufacturer reported an adjusted operating income of $288 million, marking a year-over-year increase of 15% and surpassing consensus estimates by approximately 9%.

The company's adjusted operating margin also expanded by 226 basis points, reaching 17.2%. This was achieved despite a slight decline in net sales by 0.3% year-over-year, reflecting the broader challenging market conditions.

McCormick managed to record a sequential volume improvement of 0.6% year-over-year, which was attributed to softer pricing that remained relatively flat compared to the previous year.

This was in line with the company's earlier projections. Additionally, the company benefited from strong operating leverage, which was partly due to reduced selling, general, and administrative (SG&A) expenses, including lower distribution costs and employee-related benefit expenses.

Despite the positive results in the third quarter, the company has taken a conservative stance in its forecast for the rest of the fiscal year. McCormick's updated outlook for FY 2024 implies a weaker fourth-quarter earnings per share (EPS) growth, anticipating a 12% decline year-over-year, which falls below prior market expectations.

In other recent news, McCormick & Company has reported a significant beat in third-quarter earnings per share (EPS), leading to upward adjustments in its annual sales and EPS forecasts. The company's third-quarter earnings surpassed expectations, with an adjusted EPS of $0.83, higher than the consensus estimate of $0.67.

McCormick's sales reached $1.68 billion, a slight 2.0% increase over Goldman Sachs' estimates. Despite this, Goldman Sachs maintained its Sell rating on the company, while Citi reaffirmed its Neutral stance.

The company's full-year 2024 outlook was updated, with a slight increase in adjusted EPS guidance to a range of $2.85-$2.90, primarily due to a lower expected effective tax rate. McCormick expects a 1% decline to 1% growth in constant currency net sales for 2024. The company aims to focus on strategic investments, such as digital transformation, brand marketing, and innovation to drive long-term growth.

McCormick's organic sales growth shows signs of consistent improvement, a trend that McCormick anticipates will extend into the fourth quarter and beyond into 2025.

InvestingPro Insights

McCormick & Company's recent performance and analyst adjustments are complemented by several key insights from InvestingPro. The company's market cap stands at $22.59 billion, reflecting its significant presence in the spice and flavorings industry. Despite the modest price target increase by HSBC, McCormick's stock is trading near its 52-week high, with a strong return of 20.43% over the last three months.

InvestingPro Tips highlight McCormick's impressive dividend history, having raised its dividend for 38 consecutive years and maintained payments for 54 years. This underscores the company's financial stability and commitment to shareholder returns, even in challenging market conditions. The current dividend yield is 2.0%, with a 7.69% dividend growth in the last twelve months.

However, investors should note that McCormick is trading at a relatively high P/E ratio of 27.99, which may be considered elevated relative to its near-term earnings growth potential. This valuation metric aligns with the company's cautious outlook for the fourth quarter, as mentioned in the article.

For those seeking a deeper analysis, InvestingPro offers 12 additional tips on McCormick & Company, providing a more comprehensive view of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.